Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
benzinga_article·- U.S. stocks traded lower on Tuesday, with the S&P 500 falling 0.36% to 7,690.48 and the Dow dropping 1.06% to 52,849.66. - ABM Industries Inc reported better-than-expected Q3 adjusted earnings of $1.04 per share and sales of $2.317 billion. - Crude oil gained 1.5% to trade at $92.88, while gold fell 0.8% to $4,443.00.Dyne Therapeutics: Buy Rating Backed by Late-Stage Muscle Disease Platform, Multibillion-Dollar Opportunities, and Dual-Path Approval Strategy
Tip Ranks·- Jefferies analyst Andrew Tsai maintained a buy rating on Dyne Therapeutics with a target price of 50.00 dollars. - The rating is driven by the company's advanced muscle disease platform targeting a multi-billion-dollar market with strong clinical data for treatments like z-basivarsen. - The dual-pathway approval strategy involving accelerated and functional endpoint trials provides significant upside potential and a favorable risk-reward profile.Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
benzinga_article·- U.S. stock futures declined sharply during Tuesday's pre-market session, with Dow futures falling over 400 points. - Novartis shares tumbled 12.7 % after reporting that its pelacarsen phase III Lp(a) HORIZON trial failed to meet its primary endpoint. - Other notable movers included Ionis Pharmaceuticals dropping 11.5 % in sympathy and Dyne Therapeutics dipping 35.5 %.